823803-51-6

Basic information

• Product Name: Quinoline, 8-bromo-5-methyl- (9CI)
• Synonyms: Quinoline, 8-bromo-5-methyl- (9CI);8-bromo-5-methylquinoline
• CAS NO: 823803-51-6
• Molecular Formula: C10H8BrN
• Molecular Weight: 222.08122
• Product Categories: METHYL
• Mol File: 823803-51-6.mol

Chemical Properties

• Boiling Point: 315.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.488±0.06 g/cm3(Predicted)
• PKA: 2.56±0.29(Predicted)
• CAS DataBase Reference: Quinoline, 8-bromo-5-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 8-bromo-5-methyl- (9CI)(823803-51-6)
• EPA Substance Registry System: Quinoline, 8-bromo-5-methyl- (9CI)(823803-51-6)

Safety Data

• Hazardous Substances Data: 823803-51-6(Hazardous Substances Data)

Upstream product

• 5326-34-1 4-Bromo-3-nitrotoluene 
• 53078-85-6 2-bromo-5-methylaniline 
• 107-18-6 allyl alcohol 
• 56-81-5 glycerol 

Downstream Products

• 1154741-19-1 C₁₀H₁₀BNO₂ 
• 1155264-26-8 C₂HF₃O₂*C₁₀H₁₀BNO₂ 
• 943847-28-7 8-bromo-5-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]quinoline 
• 943847-26-5 8-bromo-5-quinolinecarboxaldehyde 

Relevant articles and documents

Biaryl product formation from cross-coupling in palladium-catalyzed borylation of a Boc protected aminobromoquinoline compound

The palladium catalyzed borylation of a Boc protected aminobromoquinoline compound with bis(pinacolato)diboron yielded a biaryl compound, resulting from cross coupling, as the major product, instead of the intended boronate, even though no strong base was used. Such results indicate that under certain conditions and with certain substrates, cross coupling can be a major problem during borylation, leading to unintended consequences.

COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS

The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

From Anilines to Quinolines: Iodide- and Silver-Mediated Aerobic Double C?H Oxidative Annulation–Aromatization

Quinoline synthesis from easily accessible raw materials such as anilines is a valuable and meaningful task. Herein, we communicate an iodide- and silver-mediated C?H/C?H oxidative annulation–aromatization between anilines and allyl alcohols. This protocol provides a direct route to the synthesis of quinoline derivatives from inexpensive commodities. Various kinds of anilines, even heterocyclic anilines, were shown to be workable substrates, generating the corresponding multi-substituted quinolines in good yields.

ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR

Provided herein are antagonists la or lb of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof. (Formula I)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection